Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
32 results
D1.327 - Genetic Analysis of Children with Suspected Immunodeficiency: Mimickers of Inborn Errors of Immunity
D1.329 - Late-Childhood Diagnosis of DNA Methyltransferase 3B Deficiency-ICF1 Syndrome
D1.322 - Clinical Cardiovascular Safety Assessment of Oral Deucrictibant
D1.323 - Assessing Immune Responses to Conjugate Pneumococcal Vaccination in Infants with Transient and Unclassified Hypogammaglobulinemia:Insights from a Tertiary Pediatric Center
D1.324 - JAK Inhibitors in the Treatment of Chronic Mucocutaneous Candidiasis in a Patient with STAT1 Gain-of-Function Mutation
D1.326 - Behind The Scenes: Primary Immunodeficiencies in Pediatric Eosinophilic Gastrointestinal Diseases
D1.328 - CARD11 Dominant-Negative Mutation Presenting with Early Severe Bacterial Sepsis, Viral Susceptibility, and Alopecia Totalis in a Child
D1.330 - Two different clinical presentations, two same immunological features in Purin nucleoside phosporilase deficiency
D1.331 - Analysis of early complement parameters and C1INH values in newborns with a positive family history of HAE-C1INH
D1.333 - Digital clinical registry pilot for hereditary angioedema: standardized monthly real-world monitoring of C1 inhibitor deficiency in Serbia
D1.334 - Association of Multiple Endocrinopaties with Immune Dysregulation, Allergies and Primary Immunodeficiency
D3.440 - Long-Term Efficacy and Safety of Donidalorsen for Hereditary Angioedema Among Patients in Europe: A Regional Analysis of the OASISplus Study
D3.441 - Switching to Donidalorsen for Hereditary Angioedema: 1-Year Results From the Phase 3 OASISplus Study
D3.444 - Efficacy and Safety of Donidalorsen for Patients With Hereditary Angioedema in Europe Who Switched From Prior Long-Term Prophylaxis: Results From the OASISplus Study
D3.445 - Validation of a Novel Serum-Based Indirect Basophil Activation Test (iBAT) to Evaluate Efficacy of a Pivotal Phase III PQ Grass Immunotherapy Trial
D3.437 - Impact of benralizumab on fatigue and health-related quality of life in patients with hypereosinophilic syndrome: findings from the NATRON phase 3 trial
D3.438 - Clinical outcomes with navenibart according to baseline attack rate, body mass index, and age: results of the ALPHA-STAR trial
D3.439 - Donidalorsen For The Treatment Of Hereditary Angioedema: 1-Year Results From The OASISplus Open-Label Extension Cohort
D3.442 - Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Open-Label Extension Cohort
D3.443 - Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Switch Cohort
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download